Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Ginkgo Bioworks Holdings, Inc. filed a Form 8-K reporting a November 15, 2022 underwriting agreement for a public offering of Class A common stock. The offering closed on November 18, 2022. The filing concerns a financing transaction rather than quarterly or annual operating results.
Offering and key financial metrics
- Shares issued: 41,383,877 shares of Class A common stock.
- Offering price: $2.4164 per share paid to the Company by BTIG, LLC in a bought deal.
- Net proceeds: Approximately $99.1 million after certain offering expenses.
- Underwriter option: A 30-day option to purchase up to an additional 6,207,581 shares at $2.4164 per share.
- Use of proceeds: The proceeds offset approximately $80 million of cash used to acquire certain assets and liabilities of Bayer CropScience LP and strengthen the Company’s balance sheet.
- Liquidity and debt: The filing states that the transaction strengthened the balance sheet, but it does not provide updated cash, debt, liquidity, leverage, revenue, profit, cash-flow, or margin figures.
Material changes versus the prior comparable period
The filing does not provide comparable-period operating results. The material disclosed change is the issuance of 41,383,877 shares and the receipt of approximately $99.1 million in net proceeds after the Company elected to fund the Bayer transaction with cash rather than shares.
Guidance, outlook, risks, contingencies, and unusual items
- Management described the balance sheet as an important strategic asset in the emerging biotechnology field and current economic environment.
- The Company stated that it generally uses equity in strategic acquisitions and chose the offering to obtain greater certainty regarding the price and distribution of shares that otherwise might have been issued to Bayer.
- The share issuance creates dilution for existing common stockholders. Additional dilution could result if the underwriter exercises its option.
- The filing does not provide financial guidance or an operating outlook.
- The Bayer acquisition consideration was payable, at the Company’s election, in cash or common stock; the Company ultimately used cash on hand at closing.
Important facts for investors to verify
- Whether the underwriter exercised all or part of the 30-day option for up to 6,207,581 additional shares.
- The final number of shares outstanding after the offering and resulting ownership dilution.
- The precise acquisition assets and liabilities obtained from Bayer and the accounting treatment of the transaction.
- The Company’s updated cash balance, liquidity runway, debt obligations, and use of the remaining offering proceeds.
- Subsequent operating results and whether the financing materially affected per-share results.